Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLX 5000

Next Previous
X
Search
Drug Profile

BLX 5000

Alternative Names: BLX-5000; MLX-5000

Latest Information Update: 30 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biolexis Therapeutics
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; SESN2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 30 Aug 2024 Preclinical trials in Cardiovascular disorders in USA (PO) prior to August 2024 (Biolexis Therapeutics pipeline, August 2024)
  • 30 Aug 2024 Preclinical trials in Metabolic disorders in USA (PO) prior to August 2024 (Biolexis Therapeutics pipeline, August 2024)
  • 18 Jan 2024 Biolexis Therapeutics plans to file an IND application for Type 2 diabetes mellitus and obesity (PO) in the second quarter of 2025 (Biolexis Therapeutics pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top